LONDON--(BUSINESS WIRE)--Citi’s Issuer Services business, acting through Citibank N.A., has been appointed by Innocoll AG (“Innocoll”), a global collagen-based pharmaceutical company, as the depositary bank for their sponsored Level 3 American Depositary Receipt (ADR) programme. Innocoll’s shares trade only in the U.S. through ADRs listed on the NASDAQ Global Market, under the symbol “INNL”.
“Citi is delighted to be appointed by Innocoll as depositary bank for their Level 3 ADR programme,” Dirk Jones, Global Head of Issuer Services said, “Citi’s investor relations expertise for newly listed companies and unmatched global equity distribution network will be a powerful platform for Innocoll to manage their ADR programme going forward”.
A registration statement relating to Innocoll's securities was declared effective by the U.S. Securities and Exchange Commission on July 24, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the offered securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.
About Innocoll AG
Innocoll is a global, commercial-stage, specialty pharmaceutical company. The Company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies. The Company's late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XaraColl® in phase 3 development for the treatment of post-operative pain; Cogenzia® in phase 3 for the adjuvant treatment of infected diabetic foot ulcers; and CollaGUARD®, a barrier for the prevention of post-surgical adhesions. The Company's approved products include: CollaGUARD(Ex-US), Collatamp® G, Septocoll®, RegenePro®, Collieva®, CollaCare®, Collexa®, and Zorpreva™, which are sold through strategic partnerships with various partners including Takeda, Biomet, and Jazz Pharmaceuticals. All of the Company's products are made using Type 1 collagen and are manufactured in-house at its facility in Saal, Germany.
For more information, please visit www.innocollinc.com.
Citi, the leading global financial services company, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.
Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://new.citi.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi